SITC Archive Library

The Society for Immunotherapy of Cancer (SITC) hosted the Value of Cancer Immunotherapy Summit during the SITC 31st Annual Meeting & Associated Programs on November 11-13, 2016. Available here are the presentation slides and video.

SITC 31st Annual Meeting Organizers

• Chair: Lisa H. Butterfield, PhD – University of Pittsburgh
• James L. Gulley, MD, PhD, FACP – National Cancer Institute, National Institutes of Health
• Elizabeth A. Repasky, PhD – Roswell Park Cancer Institute
• Laura S. Wood, RN, MSN, OCN – Cleveland Clinic Taussig Cancer Institute
• Holbrook E. Kohrt, MD, PhD – Stanford Cancer Institute

Program Summary

This summit on Sunday, November 13, 2016 discussed the issues of value with respect to tumor immunotherapy bringing a variety of different perspectives to the table, including academic physicians, patient advocates, regulatory agencies and third party payors. In addition to articulating the unique features of tumor immunotherapy and the value proposition for this form of treatment, the summit resulted in a referendum on future directions and priorities for better defining the full value of tumor immunotherapy for patients with cancer. The intended audience for this program included U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care who were interested in learning about the value of cancer immunotherapy. This included, but was not limited to basic, translational and clinical researchers; post-doctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals. Organized in collaboration with the American Society of Clinical Oncology (ASCO).

About the SITC 31st Annual Meeting

SITC's 31st Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important Society projects. Following SITC’s tradition of collaborating to advance the field, the 31st Annual Meeting featured numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. An in-depth Value of Cancer Immunotherapy Summit, organized in collaboration with the American Society of Clinical Oncology, was prominently featured to discuss a crucial topic that impacts all cancer immunotherapy constituents, from researchers and clinicians to payers and cancer patients.

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.

#Researcher#SITC#AnnualMeeting#Video#2016#Clinician#PresentationSlides
#Melanoma#RenalCellCarcinoma#NonSmallCellLungCancer#AdoptiveCellTherapy
#CombinationTherapy#Cytokines#Ipilimumab#Nivolumab#Industry#Oncologist
#AdverseEvents